David “Dave” Moore is president of Novo Nordisk Inc., and executive vice president, US Operations and Global Business Development. Dave has responsibility for the operations in the US, Novo Nordisk’s largest sales region, and global business development.

From 2017 to 2019, Dave was Senior Vice President, Commercial, at Novo Nordisk Inc., US, where he led the successful transformation of the company’s commercial operating model into an integrated sales and marketing organization. He led the company through multiple new product launches, including Ozempic^®.

Dave re-joined Novo Nordisk in 2022, leading the Corporate Development organization. In this role, he and his team were responsible for driving corporate strategy activities as well as all business development and M&A activities across Novo Nordisk, including Novo Holdings A/S’ acquisition of Catalent, Inc. and Novo Nordisk’s subsequent acquisition of three manufacturing sites from Novo Holdings.

Outside Novo Nordisk, Dave has served as an investment partner at Gurnet Point Capital, CEO in the infectious disease business at Roivant Sciences, as well as president and chief commercial officer of Cempra Pharmaceuticals. Dave began his career at Johnson & Johnson, where he spent 14 years in roles of increasing responsibility. He has more than 20 years of experience in strategy, commercial, market access, business development and investing from working in both large cap pharmaceutical companies, biotech companies and within private equity.

Dave holds a degree in biology from Towson University, an MBA from Lehigh University and completed the graduate program in population health and health policy at Thomas Jefferson University.